NVSEF News and Press, Novartis Ag Basel Akt From 07/30/23

2023-07-30 09:05:25 ET Summary Alnylam partnered Roche to develop and commercialize zilebesiran for the treatment of hypertension. Alnylam's share price has not benefited as the announcement was followed by the company revealing a very long development timeline for the candidate. ...

2023-07-26 23:18:28 ET Summary Intellia is a pipeline-stage firm, leveraging gene-editing technology to develop therapies for rare diseases. NTLA is on track toward key data and regulatory catalysts. Early clinical data in HAE and ATTR have provided solid validation for Intellia's...

2023-07-23 05:45:00 ET Summary Novartis has signed a $1 billion deal to acquire DTx Pharma - DTx Pharma shareholders will receive $500 million upfront and up to $500 million in milestones. Sichuan Kelun-Biotech completed a $174 million IPO on the Hong Kong Exchange, valuing the co...

2023-07-19 12:58:12 ET Summary Swiss pharmaceutical group Novartis raised its full-year earnings forecast due to strong first half performance and plans a share buyback of up to $15 billion by 2025. The company also announced the separation of its generic drugs unit, Sandoz, throu...

2023-07-18 15:17:27 ET Summary Novartis AG Q2 2023 earnings topped Wall Street expectations on both the top and bottom lines. A $15 billion share buyback was announced and is expected to be completed by year end 2025. Novartis has several drugs in its pipeline, which should ca...

2023-07-18 13:13:08 ET Novartis AG (NVS) Q2 2023 Earnings Conference Call July 18, 2023, 8:00 AM ET Company Participants Samir Shah - Global Head, Investor Relations Vas Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference ...

2023-07-11 19:31:22 ET Summary Aclaris Therapeutics, Inc. results from a phase 2b study using zunsemetinib for the treatment of patients with rheumatoid arthritis are expected to be released by Q4 of 2023. The global rheumatoid arthritis market is expected to reach $33.3 billion b...

2023-07-06 14:48:32 ET Summary Johnson & Johnson's Supplemental Biologics Licensing Application of CARVYKTI was filed; approval would allow company to target a much earlier Multiple Myeloma patient population. Sales of CARVYTKI have not ramped up well since launch, but efforts...

2023-07-02 04:45:00 ET Summary Cellular Biomedicine Group has out-licensed global rights to its two lead CAR-T candidates to Janssen Biotech for $245 million upfront. We have more on latest deals and financings from Sichuan Kelun-Biotech, Sichuan Kelun-Biotech, Lion TCR, Beijing B...

2023-06-29 12:00:00 ET Summary Where do you put money that you need? I have some big upcoming checks to write. Here are ideas for protecting earmarked principal. Activision My Activision Blizzard, Inc. ( ATVI ) calls will be fantastic if the FTC l...